# AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07021950/  
OnCo record `nct07021950` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ivonescimab, fOLFIRI (5-FU, leucovorin, irinotecan) and bevacizumab (glioblastoma use) in colorectal cancer, run by Sun Yat-sen University, not yet recruiting.

## Summary

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07021950 by Sun Yat-sen University, with a registry enrolment figure of 130 participants, started 2025-08-10 and due to reach its primary completion in 2027-10-31. Interventions recorded: AK112; FOLFIRI; Bevacizumab. Conditions listed: Colorectal Cancer; Ivonescimab. Primary outcome: PFS. Colorectal eligibility wording from the registry: "Pathologically confirmed locally advanced unresectable or metastatic colorectal adenocarcinoma". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07021950
- Phase: 2
- Setting: Ivonescimab (AK112) Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer: a Randomized, Controlled, Multicenter Phase II Study
- Sponsor: Sun Yat-sen University
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT07021950: https://clinicaltrials.gov/study/NCT07021950

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07021950.json